Clover Health Investments, Corp. — Form 8-K Summary
Reporting date: April 22, 2024. This Form 8-K reports an executive leadership change and related compensation arrangements; it does not provide quarterly financial results.
Business Context and Reporting Period
Clover Health Investments, Corp. is a Delaware corporation whose Class A common stock trades on Nasdaq under the symbol CLOV. Peter Kuipers will become Chief Financial Officer, principal financial officer, and principal accounting officer after the Company files its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024. He will initially serve as Interim Senior Vice President of Finance beginning April 29, 2024.
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, or other operating metrics. The filing text does not provide a clear value for these items.
Material Changes Versus the Prior Comparable Period
- Peter Kuipers will succeed Terrence Ronan as Chief Financial Officer and principal financial and accounting officer following the filing of the March 31, 2024 Form 10-Q.
- Mr. Ronan will remain Interim Chief Financial Officer until Mr. Kuipers assumes the permanent role and will then cease serving as the Company’s principal financial and accounting officer.
- The appointment represents a change in executive leadership rather than a reported change in financial performance.
Compensation, Outlook, and Risks
- Mr. Kuipers will receive an annual base salary of $525,000.
- His initial target annual cash incentive bonus is 95% of base salary.
- He will receive a one-time restricted stock unit grant with a grant-date fair value of $5.0 million. Twenty-five percent will vest on the first anniversary of his start date, with the remainder vesting in 12 equal quarterly installments beginning three months after that anniversary, subject to continued service.
- He will be eligible for future incentive awards, including restricted stock units, performance stock units, or cash, at the discretion of the Talent and Compensation Committee.
- He is expected to enter into the Company’s standard executive indemnification agreement, including advancement of defense expenses.
- The filing provides no financial guidance, operating outlook, material contingency, or new business risk disclosure.
Important Facts for Investors to Verify
- Verify the effective transition date after the filing of the quarter ended March 31, 2024 Form 10-Q.
- Review the forthcoming employment agreement and RSU award documentation, which will be filed with the Form 10-Q for the quarter ending June 30, 2024.
- Assess the dilution and expense implications of the $5.0 million RSU award.
- Review the March 31, 2024 Form 10-Q separately for financial results, liquidity, debt, guidance, and risk disclosures.
- Confirm the eventual transition from Terrence Ronan to Peter Kuipers and any subsequent changes in executive compensation or responsibilities.